![]() |
|
|
Molecular Pharmacology, Vol 3, 15-27, Copyright © 1967 by the American Society for Pharmacology and Experimental Therapeutics
-Receptor
1 Theoretical Biology Unit, School of Pharmacy, State University
of New York at Buffalo, Buffalo, New York 14214
Studies have been made of the potential usefulness of adrenergic blocking 2-halogenoethylamines for labeling time
-receptor. The uptake of 3H-labeled N-(2-bromoethyl)-N-ethyl-N-1-naphthylmethylamine (3H-SY.28) by rabbit vas deferens was shown
to be nonspecific and the 2-halogenoethylamine apparently showed little specificity for
the
-receptor. In an attempt to obtain greater specificity, rabbit aorta and vas deferens
were pretreated with N,N-dimethyl-2-bromo-2-phenylethylamine, a short-lasting irreversible
-receptor antagonist, prior to treatment with 3H-SY.28. Tissues pretreated
with the short-lasting antagonist should take up less 3H-SY.28 and the difference
between this uptake and that of controls should reflect the concentration of
-receptor material. However, this treatment did not afford any significant protection
against the uptake of 3H-SY.28. The possible protective effects of various amines
against labeling by 3H-SY.28 were also investigated: no correlation could be found
between the protective ability of these amines and their "direct" or "indirect" sympathomimetic activities. An investigation was also made of the finding that trypsin
can reverse the blockade of 3H-SY.28. It was concluded that the recovery of response
following trypsin is probably unrelated to
-receptor regeneration.
The distribution of 3H-SY.28 and its corresponding alcohol was studied in rats. Our results suggest that the prolonged tissue retention of radioactivity following 3H-SY.28 is probably due to the high binding capacities of tissues for 3H-SY.28 alcohol rather than to the presence of high concentrations of covalently bound 3H-SY.28.
Note:
ACKNOWLEDGMENTS
The authors wish to thank Miss Marlene Calderone for her technical assistance.
This work was supported by Grant GM 11603
from the United States Public Health Service.